Eidos Therapeutics, Inc.·4

Dec 4, 5:34 PM ET

Sinha Uma 4

4 · Eidos Therapeutics, Inc. · Filed Dec 4, 2020

Insider Transaction Report

Form 4
Period: 2020-12-02
Sinha Uma
Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2020-12-02$90.63/sh702$63,625317,025 total
  • Sale

    Common Stock

    2020-12-02$89.63/sh3,798$340,402317,727 total
  • Sale

    Common Stock

    2020-12-02$92.97/sh200$18,593316,525 total
  • Sale

    Common Stock

    2020-12-02$91.89/sh300$27,567316,725 total
Footnotes (5)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020.
  • [F2]Represents the weighted average sale price of the shares sold ranging from $89.15 to $90.125 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5.
  • [F3]Represents the weighted average sale price of the shares sold ranging from $90.33 to $91.18 per share.
  • [F4]Represents the weighted average sale price of the shares sold ranging from $91.56 to $92.10 per share.
  • [F5]Represents the weighted average sale price of the shares sold ranging from $92.71 to $93.22 per share.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION